Amanita, Dr. Jorgenson seems to differ with your assessment. Luci A. Power seems to differ with your assessment. Alton clearly differs with your assessment. Dr. Stevenson obviously differs with your assessment.
http://cdex-inc.com/cdex-inc-appoints-dr-james-g-stevenson-to-the-cdex-board-of-directors/ I am pleased to join the Board of CDEX and look forward to working with my fellow directors to realize the full potential of CDEX’s life changing technologies. The company has developed valuable technology that could save thousands of lives every year through prevention of medication errors in the clinical environment. CDEX has a strong technology platform and vast market opportunity in healthcare and security both of which are key components for the future success of the Company. As a practicing pharmacist I recognize the prospects of the company and I will work to ensure that the best interests of shareholders, healthcare providers, and patients are represented on the board,” stated Dr. Stevenson.
In answer to your question: Both product lines provide a recurring revenue stream and address three problem areas in the healthcare market: (i) human error in the compounding of medications, with an emphasis on, but not limited to high risk medications; (ii) harmful counterfeit medications and (iii) diversion of hospital narcotics.
ValiMed™ Medication Validation System (MVS) Product Line – Consists of two products: Our third generation ValiMed known as the ValiMed CCT and the ValiMed G4 system (VG4). Both Valimed systems help healthcare providers ensure patient safety and control costs by reducing medication errors, utilizing our patented and patent pending process known as Enhanced Photoemission Spectroscopy (EPS). The VG4 system uses a patented detection process providing a real time (within seconds), quantitative (strength/concentration) as well as qualitative (identification of an unknown) analysis of high-risk single component compounded medications and treatment solutions. The Valimed CCT system that is operating in numerous hospital settings around the country, provides the healthcare industry with verification of a known substance, specifically a known drug with a known strength/concentration, in a known diluent. This current system also utilizes our proprietary cuvettes in the process. Both devices help healthcare facilities comply with Joint Commission on Accreditation of Healthcare Organizations compliance requirements and United States Pharmacopeia's General Chapter 797 Pharmaceutical Compounding—Sterile Preparations (“USP 797”) guidelines for compounding sterile preparations. Both product lines provide a recurring revenue stream and address three problem areas in the healthcare market: (i) human error in the compounding of medications, with an emphasis on, but not limited to high risk medications; (ii) harmful counterfeit medications and (iii) diversion of hospital narcotics. In the near future, we expect the VG4 product line to address multi component compounded mixtures, such as total parenteral nutrition. We expect to add oncology drugs to our formulary in 2013 as well. One of the most significant improvements with the VG4 is the capability of analyzing through most containers that are currently being used in pharmaceutical settings. This provides our end users with a more streamlined application, with less labor, without any compromising of the sterility of the compounded admixtures.
Summer Meeting 2012 Poster Listing - American Society of Health ... Board#/Day. 13-M Assessing drug residue in a robotic IV compounder, Luci Power,
Safe Handling of Hazardous Drugs Workbook by Luci A. Power ... by Luci A. Power and James Jorgenson. Overview - This workbook is the companion to the Safe Handling of Hazardous Drugs Video Training Program, and ...
Headline News: USP and NIOSH ... - ASHP CE Center Luci Power ... Luci is a primary author of both the 1985 and 1990 ASHP Technical ... of the ASHP Safe Handling of Hazardous Drugs Video Training Program.
Luci A. Power, M.S., is gratefully acknowledged for leading the revision of these guidelines. ..... Paper presented at ASHP Midyear Clinical Meeting. Atlanta, GA ...
= = = = = = = = = = = = = Hazardous Drugs as Compounded S'rerile Preparo'rions ............................................. .. 79. Luci A. Power ... Veri?ca'rion of Compounding Accuracy = = = = = = = = = = = = = = = = = by LA Power - ?Related articles Luci A. Power MS, RPh | Power Enterprises, San Francisco, CA. In 2004, two ... Pharmaceutical Compounding—Sterile Preparations, known as = = = = = = = = = = = = = = = = =
The 2012 Landscape of I.V. Medication Safety: Processes, Tools, and Training Meeting the Challenge of I.V. Safety Luci A. Power, M.S., B.S.Pharm.
ValiMed G4 The ValiMed G4 drug validation system identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents, and concentration of high-risk compounded medications and treatment solutions. This “catches” errors that may be missed with other technologies.
News 
Market Data 
Discover 
AI
